Episode 28: Inside Canada’s Drug Approval Process with Sudha Kutty of CDA-AMC (Part 1)
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
Episode 28: Inside Canada’s Drug Approval Process with Sudha Kutty of CDA-AMC (Part 1)
-
Letto da:
-
Di:
A proposito di questo titolo
Dr. Aly-Khan Lalani and Dr. Christopher Wallis sit down with the Executive Vice-President, Evidence, Products, and Services at Canada’s Drug Agency (CDA-AMC), Sudha Kutty. In part one of this series on drug approval, they discuss health technology assessments and frameworks, how CDA-AMC balances timely access with rigorous evidence review and more.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.